RE: EHA14 Jun 2026 17:22
To me it looks like as follows.
Now that HCM is firmly in the driver’s seat, their objective is straightforward:
maximize the value of their position, and do so on a realistic timeline.
They would not have taken control unless they had strong conviction in BEX’s underlying mechanism and its potential strategic value.
This also means something important for expectations:
HCM is probably not here to fund years of additional clinical development?
The idea of Faron evolving into a long‑term, independent biotech champion in Finland is no longer the relevant scenario?
The strategic path now revolves around value realization, not building an industrial footprint.
For shareholders, the key inflection point is not Phase 3 trials or eventual FDA approval?
The decisive moment is now — whether the EHA poster’s translational data provides a convincing demonstration of:
- Pharmacodynamic (PD) activity, and
- a coherent mechanism of action in real patients
For this purpose, a dataset of 10–20 patients can be sufficient.
In immuno‑oncology, early mechanistic clarity often matters more than large sample sizes.
We do not yet know whether any positive or negative interpretations of the poster are circulating after the on‑site presentation.
We will learn more through the upcoming RNS or, at the latest, during the webcast.
If the translational data provides a clear mechanistic proof, it effectively opens the acquisition window.
In that case, there is no need to wait for Phase 3 readouts — the strategic value becomes visible immediately.
At that point, the process is entirely in HCM’s hands.
They have experience creating competitive tension among large pharmaceutical companies, and they will aim to extract maximum value.
If the mechanistic proof is solid, early signs of strategic interest could emerge at any time.
Sign In
Follow the stocks
